Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature

被引:6
作者
Zhang, Chunyu [1 ]
Guo, Lirui [1 ]
Su, Zhongzhou [2 ]
Luo, Na [3 ,4 ]
Tan, Yinqiu [5 ]
Xu, Pengfei [6 ]
Ye, Liguo [1 ]
Tong, Shiao [1 ]
Liu, Haitao [7 ]
Li, Xiaobin [2 ]
Chen, Qianxue [1 ]
Tian, Daofeng [1 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan, Peoples R China
[2] Huzhou Univ, Affiliated Cent Hosp, Huzhou Cent Hosp, Dept Neurosurg, Huzhou, Peoples R China
[3] Peking Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China
[4] China Japan Friendship Hosp, Dept Neurosurg, Beijing, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Dept Neurosurg, Tongji Med Coll, Wuhan, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen, Peoples R China
[7] Jiaxing Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Jiaxing, Peoples R China
关键词
glioma; TIME landscape; prognosis; CIBERSORT; immune; CANCER-IMMUNOTHERAPY; CELL ACCUMULATION; RNA-SEQ; MACROPHAGES; GLIOBLASTOMA; PROGRESSION; NIVOLUMAB; BLOCKADE; GROWTH; PEMBROLIZUMAB;
D O I
10.3389/fcell.2021.717601
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The tumor immune microenvironment (TIME) has been recognized to be associated with sensitivity to immunotherapy and patient prognosis. Recent research demonstrates that assessing the TIME patterns on large-scale samples will expand insights into TIME and will provide guidance to formulate immunotherapy strategies for tumors. However, until now, thorough research has not yet been reported on the immune infiltration landscape of glioma. Herein, the CIBERSORT algorithm was used to unveil the TIME landscape of 1,975 glioma observations. Three TIME subtypes were established, and the TIMEscore was calculated by least absolute shrinkage and selection operator (LASSO)-Cox analysis. The high TIMEscore was distinguished by an elevated tumor mutation burden (TMB) and activation of immune-related biological process, such as IL6-JAK-STAT3 signaling and interferon gamma (IFN-gamma) response, which may demonstrate that the patients with high TIMEscore were more sensitive to immunotherapy. Multivariate analysis revealed that the TIMEscore could strongly and independently predict the prognosis of gliomas [Chinese Glioma Genome Atlas (CGGA) cohort: hazard ratio (HR): 2.134, p < 0.001; Gravendeel cohort: HR: 1.872, p < 0.001; Kamoun cohort: HR: 1.705, p < 0.001; The Cancer Genome Atlas (TCGA) cohort: HR: 2.033, p < 0.001; the combined cohort: HR: 1.626, p < 0.001], and survival advantage was evident among those who received chemotherapy. Finally, we validated the performance of the signature in human tissues from Wuhan University (WHU) dataset (HR: 15.090, p = 0.008). Our research suggested that the TIMEscore could be applied as an effective predictor for adjuvant therapy and prognosis assessment.
引用
收藏
页数:16
相关论文
共 84 条
[1]   Flow cytometric characterization of tumor-associated macrophages in experimental gliomas [J].
Badie, B ;
Schartner, JM .
NEUROSURGERY, 2000, 46 (04) :957-961
[2]  
Barbera-Guillem E, 2002, CANCER RES, V62, P7042
[3]   Predicting the functional states of human iPSC-derived neurons with single-cell RNA-seq and electrophysiology [J].
Bardy, C. ;
van den Hurk, M. ;
Kakaradov, B. ;
Erwin, J. A. ;
Jaeger, B. N. ;
Hernandez, R. V. ;
Eames, T. ;
Paucar, A. A. ;
Gorris, M. ;
Marchand, C. ;
Jappelli, R. ;
Barron, J. ;
Bryant, A. K. ;
Kellogg, M. ;
Lasken, R. S. ;
Rutten, B. P. F. ;
Steinbusch, H. W. M. ;
Yeo, G. W. ;
Gage, F. H. .
MOLECULAR PSYCHIATRY, 2016, 21 (11) :1573-1588
[4]   Transforming Growth Factor-β Signaling in Immunity and Cancer [J].
Batlle, Eduard ;
Massague, Joan .
IMMUNITY, 2019, 50 (04) :924-940
[5]   The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies [J].
Bingle, L ;
Brown, NJ ;
Lewis, CE .
JOURNAL OF PATHOLOGY, 2002, 196 (03) :254-265
[6]   GlioVis data portal for visualization and analysis of brain tumor expression datasets [J].
Bowman, Robert L. ;
Wang, Qianghu ;
Carro, Angel ;
Verhaak, Roel G. W. ;
Squatrito, Massimo .
NEURO-ONCOLOGY, 2017, 19 (01) :139-141
[7]   EMT in cancer [J].
Brabletz, Thomas ;
Kalluri, Raghu ;
Angela Nieto, M. ;
Weinberg, Robert A. .
NATURE REVIEWS CANCER, 2018, 18 (02) :128-+
[8]   Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series [J].
Chamberlain, Marc C. ;
Kim, Bryan T. .
JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (03) :561-569
[9]   TNF in the era of immune checkpoint inhibitors: friend or foe? [J].
Chen, Allen Y. ;
Wolchok, Jedd D. ;
Bass, Anne R. .
NATURE REVIEWS RHEUMATOLOGY, 2021, 17 (04) :213-223
[10]  
Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12